ACTRN12622000506796
Completed
未知
ong-term outcomes of myocarditis and pericarditis after Pfizer-BioNTech (Comirnaty) COVID-19 vaccination in children and adults
Medsafe0 sites323 target enrollmentMarch 30, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Medsafe
- Enrollment
- 323
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adults and children 12 years of age or older with a clinical diagnosis of myocarditis and/or pericarditis (includes myopericarditis), after any dose of the Pfizer vaccine, and their healthcare providers.
- •2\) A report of myocarditis and/or pericarditis has been submitted to the Centre for Adverse Reactions Monitoring (CARM) by the person themselves, or by someone on their behalf (such as a healthcare professional or family member).
- •3\) Participants will not be required to meet specific diagnostic criteria, such as the CDC criteria, to be eligible.
- •4\) Myocarditis and/or pericarditis diagnosed up to and including 28 February 2022, and at least 3 months prior to the survey (minimum of 3 months post\-diagnosis).
Exclusion Criteria
- •1\) Children \<12 years of age.
- •2\) People who have not received a clinical diagnosis of myocarditis and/or pericarditis. This includes self\-diagnosis, or where a diagnosis of myocarditis or pericarditis was considered as part of the differential diagnosis but was not given as a final diagnosis.
- •3\) Myocarditis and/or pericarditis diagnosed after 28 February 2022, and/or less than 3 months ago by the end of the specified recruitment period.
- •4\) People who experienced myocarditis and/or pericarditis after a third or subsequent dose of the Pfizer vaccine.
- •5\) People who did not receive the Pfizer vaccine prior to being diagnosed with myocarditis or pericarditis.
- •6\) People who experienced myocarditis and/or pericarditis after vaccination with another COVID\-19 vaccine (for example, the AstraZeneca vaccine).
- •7\) People who have not provided sufficient contact information in CARM report to be able to make initial contact.
- •8\) Circumstances that interfere with the participant’s ability to give informed consent (including a diminished understanding or comprehension of English and an interpreter unavailable).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)MyocarditisNCT06189053ModernaTX, Inc.1,500
Recruiting
Phase 3
Colchicine effects on Major Adverse Cardiac Events in patients who underwent PCIIRCT20230801059005N1Shiraz University of Medical Sciences204
Active, not recruiting
Not Applicable
The short and long-term consequences of critical illness on the heart and blood vesselsMajor adverse cardiovasular events and arrhythmiaCirculatory SystemISRCTN15905609niversity of Oxford80,000
Recruiting
Not Applicable
MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance StudyMyocarditisMyocarditis AcutePericarditisPericarditis AcuteNCT06103123Cardiology Research UBC500
Completed
Not Applicable
ong-term myocadial involvement and clinical outcome in post-COVID-19 conditioPost-COVID19 syndromeDRKS00032954Helios Universitätsklinikum Wuppertal194